Roche’s entrectinib shrinks lung tumours with two-year response duration
pharmafile | September 25, 2018 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Cancer, NSCLC, NSCLC< lung cancer, Roche, entrectinib
Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), showing the drug had long-term effects and reduced tumour size.
ROS1 gene fusions are present in around 1-2% of NSCLC patients, with NSCLC being the most common kind of lung cancer, accounting for 85% of all cases. Additionally, around 30-40% of ROS1-positive NSCLC have brain metastases at the time they receive their diagnosis.
In the studies, entrectinib demonstrated an objective response rate of 77.4%, shrinking tumours in more than three quarters of participants; furthermore, the drug also shrank tumours in 55% of patients with cancer of the central nervous system, and demonstrated a duration of response of 24.6 months.
“These results show the potential of precision medicines to deliver tailored and effective treatment options for people with non-small cell lung cancer, including those whose tumours have spread to the central nervous system,” said Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “We are also investigating entrectinib in NTRK fusion-positive tumours across several different cancer types, and look forward to presenting those results in the near future.”
Roche confirmed that this data will be presented at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, and will also be utilised in submissions to regulatory authorities around the world as it tries to secure approval for entrectinib.
Matt Fellows
Related Content
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …
